{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T05:47:10Z","timestamp":1648964830295},"reference-count":3,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6,1]]},"DOI":"10.2146\/ajhp110539","type":"journal-article","created":{"date-parts":[[2012,5,20]],"date-time":"2012-05-20T11:22:52Z","timestamp":1337512972000},"page":"931-931","source":"Crossref","is-referenced-by-count":1,"title":["Fidaxomicin: Balancing evidence and economics"],"prefix":"10.1093","volume":"69","author":[{"given":"Vanessa","family":"Stevens","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolas","family":"Onufrak","sequence":"additional","affiliation":[{"name":"Center for Health Outcomes, Pharmacoinformatics, and Epidemiology 315 Hochstetter Hall School of Pharmacy and Pharmaceutical Sciences State University of New York at Buffalo Buffalo, NY 14260"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jack","family":"Brown","sequence":"additional","affiliation":[{"name":"Center for Health Outcomes, Pharmacoinformatics, and Epidemiology 315 Hochstetter Hall School of Pharmacy and Pharmaceutical Sciences State University of New York at Buffalo Buffalo, NY 14260"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"2019041606595448100_b1-0690931","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2146\/ajhp110371","article-title":"Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection","volume":"69","author":"Crawford","year":"2012","journal-title":"Am J Health-Syst Pharm."},{"key":"2019041606595448100_b2-0690931","unstructured":"Food and Drug Administration. Dificid (fidaxomicin tablets) for the treatment of Clostridium difficile infection (CDI), also known as Clostridium difficile-associated diarrhea (CDAD), and for reducing the risk of recurrence when used for treatment of initial CDI: NDA 201699. www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/Anti-InfectiveDrugsAdvisoryCommittee\/UCM249354.pdf (accessed 2011 Aug 24)."},{"key":"2019041606595448100_b3-0690931","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/69\/11\/931\/28455095\/ajhp0931.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T11:00:46Z","timestamp":1555412446000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/69\/11\/931\/5112559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,1]]},"references-count":3,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,6,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp110539","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,6,1]]},"published":{"date-parts":[[2012,6,1]]}}}